ArticleMedical science monitor : international medical journal of experimental and clinical research2017
Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cubosome-Based Nanocarriers in Cancer Therapy: Design Optimization, Analytical Characterization, and Translational Perspectives.Annals of biomedical engineering · 2026Review
- Raloxifene-Loaded Lipid Nanovesicles: A Journey to Select the Optimal Nanocarrier Formulation Through Characterization and Cytotoxic Analysis.Biomedicines · 2025Article
- Comparative in-vitro and in-vivo evaluation of spherulites and cubosomes of Irinotecan for lung targeting.Therapeutic delivery · 2025Article
- Cubosomes: An Emerging and Promising Drug Delivery System for Enhancing Cancer Therapy.Current pharmaceutical biotechnology · 2024Review
- pH-Responsive Hybrid Nanoassemblies for Cancer Treatment: Formulation Development, Optimization, and In Vitro Therapeutic Performance.Pharmaceutics · 2023Article
- Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.Journal of drug delivery science and technology · 2022Review
- Review
- A Versatile Nanocarrier-Cubosomes, Characterization, and Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Bioactive Loaded Novel Nano-Formulations for Targeted Drug Delivery and Their Therapeutic Potential.Pharmaceutics · 2022Review
- Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review.Pharmaceutics · 2022Review
- Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance.Drug delivery · 2021Article
- Comprehensive and comparative studies on nanocytotoxicity of glyceryl monooleate- and phytantriol-based lipid liquid crystalline nanoparticles.Journal of nanobiotechnology · 2021Article
- Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles.Acta pharmaceutica Sinica. B · 2021Review
- A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy.International journal of nanomedicine · 2021Article
- Theranostic combinatorial drug-loaded coated cubosomes for enhanced targeting and efficacy against cancer cells.Cell death & disease · 2020Article
- Anticancer Activity of Thymoquinone Cubic Phase Nanoparticles Against Human Breast Cancer: Formulation, Cytotoxicity and Subcellular Localization.International journal of nanomedicine · 2020Article
- AT101-Loaded Cubosomes as an Alternative for Improved Glioblastoma Therapy.International journal of nanomedicine · 2020Article
- Novel Drug Delivery Systems for Loading of Natural Plant Extracts and Their Biomedical Applications.International journal of nanomedicine · 2020Review
- Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to develop a novel Poloxamer-based drug delivery system featuring a tumor-targeting folate moiety, which was expected to provide better targeting properties and therapeutic effects compared with the traditional cubosomes (Cubs). MATERIAL AND METHODS Both folate-modified Cubs containing etoposide (ETP-Cubs-FA) and normal cubic nanoparticles loaded with etoposide (ETP-Cubs) were prepared through the fragmentation of bulk gels under the homogenization condition of 1500 bar, and a mean particle size of around 180 nm was obtained with a narrow size distribution. The cubosomes were further characterized by differential scanning calorimetry (DSC) and Polarized light microscopy (PLM). The release of ETP in vitro from these nanoparticles was found to be 82.5% at 36 h, showing a sustained release property compared with the free drug administration. RESULTS Folate-modified cubosomes exhibited best anti-proliferative activity followed by normal cubosomes and the free drug. A further cell uptake study of Rhodamine B-loaded Cubs-FA (Rh-B-Cubs-FA) showed a marked increase of cellular accumulation compared with free Rh-B and Rh-B-loaded Cubs (Rh-B-Cubs). In vivo Rh-B-based tumor imaging demonstrated that Cubs-FA specifically targeted the tumor tissue. CONCLUSIONS The folate-modified cubosomes containing ETP may be a promising drug candidate for antitumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.